ANL 29.68 Increased By ▲ 1.38 (4.88%)
ASC 20.22 Decreased By ▼ -0.03 (-0.15%)
ASL 24.98 Decreased By ▼ -0.12 (-0.48%)
BOP 8.28 Increased By ▲ 0.03 (0.36%)
BYCO 10.31 Increased By ▲ 0.17 (1.68%)
FCCL 22.20 Increased By ▲ 0.28 (1.28%)
FFBL 26.70 Decreased By ▼ -0.05 (-0.19%)
FFL 20.25 Increased By ▲ 0.15 (0.75%)
FNEL 9.03 Increased By ▲ 0.09 (1.01%)
GGGL 27.40 Increased By ▲ 1.15 (4.38%)
GGL 45.63 Increased By ▲ 3.01 (7.06%)
HUMNL 7.28 Increased By ▲ 0.08 (1.11%)
JSCL 21.85 Increased By ▲ 0.45 (2.1%)
KAPCO 39.60 Increased By ▲ 0.41 (1.05%)
KEL 3.91 Increased By ▲ 0.05 (1.3%)
MDTL 3.64 Increased By ▲ 0.10 (2.82%)
MLCF 45.54 Increased By ▲ 1.54 (3.5%)
NETSOL 161.80 Increased By ▲ 3.29 (2.08%)
PACE 7.45 Increased By ▲ 0.25 (3.47%)
PAEL 33.30 Increased By ▲ 0.50 (1.52%)
PIBTL 11.15 Increased By ▲ 0.11 (1%)
POWER 9.20 Increased By ▲ 0.09 (0.99%)
PRL 23.90 Increased By ▲ 0.95 (4.14%)
PTC 12.12 Increased By ▲ 0.29 (2.45%)
SILK 1.79 Increased By ▲ 0.03 (1.7%)
SNGP 50.60 Increased By ▲ 1.10 (2.22%)
TELE 17.04 Increased By ▲ 1.24 (7.85%)
TRG 162.50 Increased By ▲ 4.30 (2.72%)
UNITY 40.80 Increased By ▲ 0.80 (2%)
WTL 3.67 Increased By ▲ 0.15 (4.26%)
BR100 5,189 Increased By ▲ 64.21 (1.25%)
BR30 26,249 Increased By ▲ 598.06 (2.33%)
KSE100 47,758 Increased By ▲ 305.07 (0.64%)
KSE30 19,110 Increased By ▲ 124.84 (0.66%)

Coronavirus
VERY HIGH Source: covid.gov.pk
Pakistan Deaths
23,575
4624hr
Pakistan Cases
1,047,999
4,72224hr
8.15% positivity
Sindh
389,699
Punjab
359,321
Balochistan
30,749
Islamabad
88,676
KPK
145,862
World

AstraZeneca may have provided incomplete data from latest COVID trial: US Agency

  • The Data Safety Monitoring Board has expressed concern that AstraZeneca may have included outdated information from the trial
  • AstraZeneca says safety of the vaccine has been extensively studied in phase III clinical trials and peer-reviewed data confirms the vaccine has been generally well tolerated
Updated 23 Mar 2021

(Karachi) Amid speculations about patients developing post-jab blood clots by AstraZeneca's COVID-19 vaccine, the US National Institute of Allergy and Infectious Diseases (NIAID) has showed concern that the British drugmaker may have provided an incomplete data of its vaccine's efficacy, local media reported.

"The Data Safety Monitoring Board (DSMB) has expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data," the US agency said.

The NIAID stated, "We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible."

Meanwhile, AstraZeneca which developed the vaccine in cooperation with Oxford University, has defended the safety of its product. The firm stated that the safety of the vaccine has been extensively studied in phase III clinical trials and peer-reviewed data confirms the vaccine has been generally well tolerated.

Earlier, several European and Scandinavian states including Denmark, Norway and Iceland temporarily suspended the use of AstraZeneca's Covid-19 vaccine after fears of developing post-jab blood clots. Later, they resumed AstraZeneca vaccinations after the European Medicines Agency said hat the jab is "safe and effective" and is not linked to an increased risk of blood clots.

In September 2020, AstraZeneca had suspended global trials of its experimental coronavirus vaccine after an unexplained illness in a participant in Britain.

The vaccine had been described by the World Health Organization as probably the world's leading candidate and the furthest developed.